Lisa Lewin, Author at Precision Value & Health

On-Demand Webinar – Make Market Access Your Brand’s Super Power

Lisa Lewin2022-12-01T00:14:12+00:00Events, Thought Leadership|

Doctors say it to sales reps all the time: “I like your drug and want to write it, but I can’t.” Where does your rep go from there?

New research indicates that 50% of an HCPs’ prescribing decision is based on their perception of accessibility. (But perception and reality can be two vastly different things.)

Marketers can’t change how accessible their products are, but they can change how HCPs view their brands’ accessibility on healthcare plans. In this webinar, you’ll hear about:

The most threatening market access challenges pharma brand leaders face today
Real-world stories of how top brands overcome these challenges and grow market share
Tangible tactics you can quickly implement to start making pull-through headway fast

This solution-focused, truth-packed session is a great fit for market access marketers, brand marketers and sales leaders who are interested in making their brands’ market access a top advantage over the competition.

WATCH ON DEMAND HERE

Mitigating climate health isn’t just the physician’s job – It’s a job for everyone

Lisa Lewin2022-11-30T22:38:37+00:00Thought Leadership|

Changes in climate and extreme weather affect every stakeholder in the healthcare system, not just the physicians on the front lines. Precision’s Cynthia Miller suggests we need a patient focused strategy to manage environmental risk and offers solutions that align with incentives.

READ THE ARTICLE HERE!

On-Demand Webinar – Paying for Prevention? Payer Access Challenges and Solutions for Preventative Gene Therapies

Lisa Lewin2022-11-30T22:12:14+00:00Events, Thought Leadership|

In this upcoming one-hour webinar, PRECISONadvisors Vice President Richard Macaulay will moderate a lively discussion with our panel of European payer experts as they examine the next generation of gene therapies, and weigh considerations for policy makers as well as manufacturers.

Issues to be discussed by the panel will include:

-Gene therapy treatments for diseases that take years to develop (e.g. Huntington’s Disease, Prion diseases)
-Gene Therapies to prevent development of diseases in genetically susceptible individuals (e.g. early-onset familial Alzheimer’s disease)
-Gene therapies to be used in utero (with the potential to treat lethal and morbid perinatal diseases before birth, as well as potentially using existing gene therapies much earlier in disease progression).

The discussion will conclude with a live Q&A.

WATCH ON DEMAND HERE

From Volume-to-Value—The Critical Role of EHR

Lisa Lewin2022-11-30T21:10:38+00:00Thought Leadership|

Today more than 90% of healthcare professionals are on an Electronic Health Records (EHR), and more than five hours of an eight-hour day are spent in the EHR. In parallel, life sciences companies have become increasingly aware of the ability to harness EHR data to solve for numerous challenges both in the pre-approval and post-commercialization arenas. Precision’s Ross Maclean, Matt Pitzel, Thad Nowakowski and Tim Van Aken discuss four examples of innovative applications that are gaining traction.

Read the full article here!

Emerging Threats to Health Equity

Lisa Lewin2022-11-30T20:54:34+00:00Thought Leadership|

Policy changes that expanded enrollment in Medicaid and Health Exchange plans are at risk. Precision’s Cynthia Miller and Maureen Hennessey discuss why discontinuing the policy changes will contribute to health inequities in myriad ways, and identify the essential role pharmaceutical companies can play in mitigating the impact.

READ NOW!

Brainstorming brain freeze? Try ‘Wild Cards’

Lisa Lewin2022-11-30T19:44:05+00:00Thought Leadership|

MM+M sits down with PRECISIONeffect’s SVP, Innovation Director, Simon Wilson, to chat about the agency’s new brainstorming app, Wild Cards, a free app designed to invigorate the brainstorming process and help marketers to consider new, innovative, and creative ideas.

Learn more here!

Current State and Outlook for Digital Therapeutics in Europe

Lisa Lewin2022-12-19T15:16:38+00:00Thought Leadership|

In this new downloadable brief, PRECISIONadvisors experts Katherine Leong and David Carr provide a quick overview of the current digital therapeutics landscape in Europe, taking a closer look at the rapidly-expanding list of interventions as well as the varied ways that EU countries are approaching policy, regulation and reimbursement. Katherine and David also do some forecasting looking at the future outlook for access across Europe, and provide some considerations for manufacturers and suggestions for overall pricing and reimbursement strategies.

Read now!

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective

Lisa Lewin2022-11-29T23:17:22+00:00Thought Leadership|

While treatment advances have improved overall survival in some metastatic breast cancer (mBC) subtypes, there remains no cure for mBC. Considering the use of progression-free survival and other surrogate endpoints in clinical trials, it’s useful to understand patient perspectives on measures used to assess treatment efficacy. Precision’s Suepattra May-Slater co-authored an important paper exploring global patient perceptions and their potential relation to quality of life, identifying considerations for the design and conduct of future clinical trials in mBC, as well as HTA and reimbursement decision-making, to better capture the potential value of a therapeutic innovation.

Read the paper here!

Download Now: Market access pull-through drives radical Rx growth

Lisa Lewin2022-12-26T17:31:57+00:00Events, Thought Leadership|

Want to boost sales with HCP specific market access pull-through messaging tailored to your patient population? Discover how Access Genius can drive radical brand prescription growth and amplify sales with a 4:1 proven ROI.

Download the Infographic here to learn more!

Leaping the Next Hurdle in CAR T-Cell Therapies

Lisa Lewin2022-12-12T15:47:02+00:00Thought Leadership|

While chimeric antigen receptor (CAR) T-cell therapy has demonstrated its ability to produce responses in refractory tumors, many challenges remain with the therapies. Precision’s Phil Cyr discusses some of these challenges as well as questions and research that remain to be answered.

Read the full article here!

About Lisa Lewin